TreVita, a U.S.-based medical travel company, announced on September 23, 2026, the expansion of its regenerative medicine program in Zona Río, Baja California, Mexico. The move broadens the company's stem cell services into additional therapeutic areas, including healthy aging and rejuvenation, sports and orthopedic injuries, and other conditions. The expansion signals TreVita's growing commitment to regenerative medicine as a core component of its medical travel platform.
The program's expansion comes amid surging interest in regenerative medicine among Americans seeking new approaches to health, recovery, and longevity. According to Grand View Research, the U.S. regenerative medicine market generated approximately $19.5 billion in 2024 and is projected to reach $49.3 billion by 2030, growing at a compound annual rate of about 16.8% from 2025 through 2030. This rapid growth underscores the increasing demand for innovative treatments and the need for reliable, transparent providers.
TreVita's approach emphasizes individualized physician evaluation rather than predetermined treatment packages. The process begins with a comprehensive medical review, where physicians assess a client's medical history, current condition, diagnostic information, and treatment goals before determining whether the client may be an appropriate candidate and what approach, if any, should be considered. A central focus is transparency around the cellular products clients receive, including cell type and source, cell count, cell viability, delivery method, and the physician's rationale for the treatment plan. Testing and documentation are provided to each client.
"Regenerative medicine is an increasingly important part of the healthcare conversation, but it is also a category where clients need clarity, transparency and strong medical oversight," said Blake Schroeder, CEO of TreVita. "Our goal is to help clients understand their options, remove barriers, connect them with experienced physicians and create a care experience built around safety, care, integrity and support - and most importantly, increased healthspan."
TreVita provides end-to-end support, from medical review and treatment planning through travel coordination, treatment, and post-care follow-up. The company also assists with physician consultations, medical records and diagnostic review, and care coordination. This comprehensive approach aims to remove barriers and ensure a seamless experience for clients traveling abroad for care.
The expansion is part of TreVita's broader long-term investment in regenerative medicine. The company is developing additional clinical and laboratory capabilities in Zona Río to give it greater involvement across the client journey, from medical evaluation and treatment coordination to cellular quality oversight and follow-up care. "Our vision is to increase healthspan for our clients. That is far broader than a company that simply helps someone travel for a procedure," Schroeder added. "We are building a regenerative medicine platform where the physicians, the science, the cellular product and the client experience are connected."
For American consumers, the expansion offers more options for accessing regenerative therapies outside the United States, where such treatments may be limited or costly. However, TreVita cautions that it does not represent stem cell therapies as cures and does not guarantee outcomes for any disease, injury, or medical condition. Treatment recommendations are made by physicians based on individual medical circumstances, and services are available to qualifying clients through TreVita's U.S.-based care team.
The announcement, originally distributed via NEWMEDIAWIRE, highlights TreVita's role in the evolving medical travel industry. As the regenerative medicine market continues to expand, TreVita's focus on transparency and individualized care may set a standard for others in the sector. More information about the company is available at TreVita.
